Glossary Adapted from Helping the Student with Diabetes Succeed – a Guide for School Personnel
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Living with Diabetes in the Family Iabetes Affects All Members of the Family, Fat Diet and the Twice-Daily Insulin Injections
SA JOURNAL OF DIABETES & VASCULAR DISEASE REVIEW References 10. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue KC. The diagnosis of and management of monogenic diabetes in children and adolescents. Pediat Diabetes 1. Neel J. Diabetes mellitus: a geneticist’s nightmare. In: Creutzfeldt W, Kobberling 2009; 10(suppl 12): 33–42. J, Neel JV, eds. The Genetics of Diabetes Mellitus. Berlin: Springer-Verlag, 1976: 11. Slingerland AS. Monogenic diabetes in children and adults: Challenges for 1–11. researcher, clinician and patient. Rev Endocr Metab Disord 2006; 7: 171–185. 2. Keen H. The genetics of diabetes: from nightmare to headache. Br Med J 1987; 12. Barrett TG. Differential diagnosis of type 1 diabetes: which genetic syndromes 294: 917–919. need to be considered? Pediat Diabetes 2007; 8(suppl 6): 15–23. 3. Rotter JI. The modes of inheritance of insulin-dependent diabetes mellitus or the 13. Clinical genetics and genetic counseling. In: Jorde LB, et al., eds. Medical genetics of IDDM, no longer a nightmare but still a headache. Am J Hum Genet Genetics, 2nd edn. St Louis: Mosby, 1999: 292. 1981; 33: 835–851. 14. The National Society of Genetic Counselor’s Task Force: Resta R, et al. A new 4. Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification definition of genetic counselling: National Society of Genetic Counselor’s Task of diabetes in children and adolescents. Pediat Diabetes 2009; 10(suppl 12): 3–12 Force report. J Genet Couns 2006; 15(2): 77–83. 5. Jahromi MM, Eisenbarth GS. Cellular and molecular pathogenesis of type 1A 15. -
Diabetic Ketoacidosis and Hyperosmolar BMJ: First Published As 10.1136/Bmj.L1114 on 29 May 2019
STATE OF THE ART REVIEW Diabetic ketoacidosis and hyperosmolar BMJ: first published as 10.1136/bmj.l1114 on 29 May 2019. Downloaded from hyperglycemic syndrome: review of acute decompensated diabetes in adult patients Esra Karslioglu French,1 Amy C Donihi,2 Mary T Korytkowski1 1Division of Endocrinology and Metabolism, Department of ABSTRACT Medicine, University of Pittsburgh, Pittsburgh, PA, USA Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome (HHS) are life threatening 2University of Pittsburgh School of complications that occur in patients with diabetes. In addition to timely identification of the Pharmacy, Pittsburgh, PA, USA Correspondence to: M Korytkowski precipitating cause, the first step in acute management of these disorders includes aggressive [email protected] administration of intravenous fluids with appropriate replacement of electrolytes (primarily Cite this as: BMJ 2019;365:l1114 doi: 10.1136/bmj.l1114 potassium). In patients with diabetic ketoacidosis, this is always followed by administration Series explanation: State of the of insulin, usually via an intravenous insulin infusion that is continued until resolution of Art Reviews are commissioned on the basis of their relevance to ketonemia, but potentially via the subcutaneous route in mild cases. Careful monitoring academics and specialists in the US and internationally. For this reason by experienced physicians is needed during treatment for diabetic ketoacidosis and HHS. they are written predominantly by Common pitfalls in management include premature termination of intravenous insulin US authors therapy and insufficient timing or dosing of subcutaneous insulin before discontinuation of intravenous insulin. This review covers recommendations for acute management of diabetic ketoacidosis and HHS, the complications associated with these disorders, and methods for http://www.bmj.com/ preventing recurrence. -
Glossary of Common Diabetes Terms
Glossary of Common Diabetes Terms A1C: a test that reveals exactly how well your blood sugar (glucose) has been controlled over the previous three months Beta cells: cells found in the pancreas that make insulin Blood glucose: also known as blood sugar, glucose comes from food and is then carried through the blood to deliver energy to cells Blood glucose meter: a small medical device used to check blood glucose levels Blood glucose monitoring: the simple blood test used to check the amount of glucose in the blood; a tiny drop of blood, taken by pricking a finger, is placed on a test strip and inserted in the meter for reading Diabetes: the shortened name for diabetes mellitus, the condition in which the pancreas doesn’t produce enough insulin or your body is unable to use insulin to move glucose into cells of the body Diabetic retinopathy: the eye disease that occurs in someone with diabetes when the small blood vessels of the retina become swollen and leak liquid into the retina, blurring vision; it can sometimes lead to blindness Gestational diabetes: the diabetes some women develop during pregnancy; it typically subsides after the baby is delivered, but many women who have had gestational diabetes may develop type 2 diabetes later in life Glucagon: the hormone that is injected into a person with diabetes to raise their blood glucose level when it’s very low (hypoglycemia) Glucose: blood sugar that gives energy to cells Hyperglycemia: also known as high blood glucose, this condition occurs when your blood glucose level is too high; -
Country-Specific Glucose Monitor List
Country-Specific Glucose Monitor List Country Name: Middle East and Africa (Bahrain, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia (KSA), Sudan, U.A.E.) Important Information This is a non-comprehensive list, current as of November 2016. Absence of a specific glucose monitor or test strips from this list does NOT imply compatibility or incompatibility with EXTRANEAL (Icodextrin) PD solution. Similarly, other glucose-measuring technologies which are not listed below (such as continuous glucose monitoring systems) may or may not be compatible with EXTRANEAL. Always contact the device manufacturer for current information. If the manufacturer cannot provide information regarding compatibility of the device with icodextrin and maltose, Baxter does NOT recommend that EXTRANEAL patients use the product. Baxter reserves the right to change this list without notice and does not represent that it includes all potentially incompatible products. The glucose monitor manufacturers listed have certified to Baxter that they have tested (as per ISO 15197) their monitors with maltose and icodextrin to Baxter’s recommended limits: 278 mg/dL (maltose) and 1094 mg/dL (icodextrin). The manufacturers certified that their “green” monitors, below, showed no interference of blood glucose readings under these conditions, with the exception of the “green” monitors specifically notated 4 for which certification of testing to Baxter’s recommended limits has not yet been received. Please note that the compatibility list below is only for brand-name monitors used with the corresponding brand-name test strip. If a brand-name monitor is used with another manufacture’s test strip, always contact the test strip manufacturer for current information. -
Blood Glucose Meters
BLOOD GLUCOSE METERS BLOOD DROP SIZE Meters specify how much blood, in microliters, is needed to get an accurate reading. Some meters allow you to reapply blood within a few seconds if your sample size was too small, so you don’t waste a strip. 1.5 1.0 0.8 0.7 FREESTYLE PRECISION NEO Blood Drop Size Blood Drop 0.6 0.5 0.4 0.3 FEATURES: BLOOD SAMPLE SIZE*: 0.6 BATTERY: 2 CR2032 KEY MSRP: $24.99 = audio capability = port light STRIP MSRP: 44¢/strip = backlight = logs insulin dose ($21.99/50 strips) BP = measures both blood + = calculates insulin dose glucose and blood = meter program offers Strips are compatible with the pressure access to certified meter built into the FreeStyle = wireless Bluetooth diabetes educators Libre reader capability = app compatible ADVOCATE = requires user coding * = microliters C advocatemeters.com = can save data to the ** = sold only with 888-469-3579 cloud without having insulin pump to push the data to MSRP = manufacturer’s suggested ADVOCATE REDI-CODE another device retail price. These are PLUS SPEAKING METER = computer download over-the-counter retail FEATURES: capability prices; check with your BLOOD SAMPLE SIZE*: 1.0 K = also tests blood ketones insurance plan for specific BATTERY: 2 AAA P = communicates with coverage and out-of- MSRP: $29.99 insulin pump pocket costs. STRIPS MSRP: 50¢/strip ($24.99/50 strips) ABBOTT DIABETES CARE AGAMATRIX myfreestyle.com agamatrix.com 888-522-5226 866-906-4197 FREESTYLE FREEDOM LITE JAZZ WIRELESS 2 FEATURES: FEATURES: BLOOD SAMPLE SIZE*: 0.3 BLOOD SAMPLE SIZE*: 0.5 -
Decrease of Fructosamine Levels During Treatment with Adalimumab
European Journal of Endocrinology (2007) 156 291–293 ISSN 0804-4643 CASE REPORT Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis I C van Eijk1, M J L Peters1,2, M T Nurmohamed1,2,3, A W van Deutekom4, B A C Dijkmans1,2 and S Simsek4 1Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands, 2Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands, 3Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands and 4Department of Endocrinology/Diabetes Center, VU University Medical Center, PO Box 7057, 1007 MB, Boelelaan 1117, Amsterdam, The Netherlands (Correspondence should be addressed to S Simsek; Email: [email protected]) Abstract Tumour necrosis factor a (TNFa) is a pro-inflammatory cytokine which has been closely linked to obesity and insulin resistance. We present two cases of patients with rheumatoid arthritis (RA) and concomitant diabetes mellitus, who showed a marked decrease of fructosamine levels after initiating therapy with adalimumab, a TNFa-blocking agent, for active RA. This finding may implicate that TNFa blockade causes better glycaemic control in RA patients with concomitant diabetes, possibly by improving insulin resistance. European Journal of Endocrinology 156 291–293 Introduction Research design and methods Tumour necrosis factor a (TNFa), a pro-inflammatory A patient with known diabetes type 1 and concomitant cytokine, plays an important role in inflammatory and RA showed a marked improvement of HbA1c levels after autoimmune diseases like rheumatoid arthritis (RA). initiation of adalimumab, a recombinant human IgG1- TNFa has also been closely linked to obesity and insulin MAB, therapy for active RA when she visited the resistance (1). -
Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients with Type 2 Diabetes: a Prospective Study
Open Access Original Article DOI: 10.7759/cureus.11195 Patient Satisfaction and Clinical Efficacy of Novel Blood Glucose Meters Featuring Color Range Indicators in Patients With Type 2 Diabetes: A Prospective Study Ayman Al Hayek 1 , Asirvatham Alwin Robert 1 , Mohamed Al Dawish 1 1. Department of Endocrinology and Diabetes, Prince Sultan Military Medical City, Riyadh, SAU Corresponding author: Ayman Al Hayek, [email protected] Abstract Introduction Self-monitoring of blood glucose (SMBG) plays an important role in diabetes management. The Contour®Next One glucometer is a recent glucometer that delivers blood glucose results by an immediate color indicator to aware users when blood glucose is at a critical high or low. The main purpose of the study was to assess the impact of an application of a blood glucose meter (BGM) having a color range indicator on clinical characteristics and glucose monitoring satisfaction (GMS) among patients having type 2 diabetes (T2D). Methods A total of 85 (male 42 and female 43) patients with T2D were switched to a BGM having smartLIGHT™ target range indicator (blood glucose meters featuring color range indicator) using Contour®Next One glucometer. Demographic data, as well as glycemic control, were collected at baseline and 12 weeks. At the time of the baseline and 12 weeks of the study, a trained interviewer gave the GMS survey questionnaire to every patient in order to collect the glucose monitoring satisfaction. In addition to GMS, a patient’s perceptions of smartLIGHT™ feature satisfaction survey responses were also collected from the patients at the end of the study (12 weeks). -
Diabetic Coma
University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1932 Diabetic coma J. Milton Margolin University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Margolin, J. Milton, "Diabetic coma" (1932). MD Theses. 218. https://digitalcommons.unmc.edu/mdtheses/218 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. DIAB3TIC COMA J. MIJ/rON 1l1LARGOLIN THE illnVERSITY OF NlsBRASKA COLLEGE OF ~~DICINE -- OMAHA, NEBHASKA 1932 - DIAB3TIG COl£.<\ Diabetic coma is a true medical emergency. It is just as much an emergency as an acute appendicitis or an incarcerated hernia, and as in the latter condition, with every hour that passes without treatment the chances for life decrease. It is early intervention that counts. Therefore, a physician should never let an engagement or any personal desires keep him from the bedside of a patient whom he thinks may be in coma. HISTORY Diabetic coma has been known as a clinical entity since l8bO when a German, Von Dusch and a Scotchman, March firs t de scri bed it. 'l'wen ty years later, Kus smaul publ i shed his classical description of diabetic coma. It is the IlKussmaul breathing, II as described by the author which is the outstanding and characteristic feature of diabetic coma. -
Diabetes Is a Disease in Which the Body's Ability to Produce Or Respond
Early Signs and Symptoms of diabetes: Early symptoms of diabetes, especially type 2 diabetes, can be subtle or seemingly harmless. Over time, however, you may Diabetes is a disease in which the develop diabetes complications, even if you body’s ability to produce or respond to haven't had diabetes symptoms. In the the hormone insulin is impaired, United States alone, more than 8 million resulting in abnormal metabolism of people have undiagnosed diabetes, Treatments: carbohydrates and elevated levels of according to the American Diabetes Association. Understanding possible glucose (sugar) in the blood. • Insulin therapy diabetes symptoms can lead to early • Oral medications diagnosis and treatment and a lifetime of Diabetes can be broken down into • better health. If you're experiencing any of Diet changes two types, Type 1 and Type 2. Type 1 • Exercise diabetes involves the the following diabetes signs and symptoms, see your doctor. body attacking itself by The medications you take vary by mistake, this then the type of diabetes and how well the causes the body to stop making insulin. With medicine controls you blood glucose levels. Type 2 diabetes the Type 1 diabetics must have insulin. Type 2 body does not respond may or may not include insulin and may just like it should to the be controlled with diet and exercise alone. insulin the pancreas is If you notice any of these changes notify making. Your body tells the pancreas that it needs to make more insulin since the your health care provider. The earlier • insulin that is already there is not working. -
Kv-Ada-Jdbc210013 1..3
Diabetes Care Volume 44, June 2021 e1 Performance of the Insulin-Only Luz E. Castellanos,1 Courtney A. Balliro,1 Jordan S. Sherwood,1 Rabab Jafri,1 iLet Bionic Pancreas and the Mallory A. Hillard,1 Evelyn Greaux,1 Rajendranath Selagamsetty,2 Hui Zheng,3 Bihormonal iLet Using Firas H. El-Khatib,2 Edward R. Damiano,2,4 and Dasiglucagon in Adults With Type Steven J. Russell1 1 Diabetes in a Home-Use Setting Diabetes Care 2021;44:e1–e3 | https://doi.org/10.2337/DC20-1086 Reductions in blood glucose levels in with insulin lispro (Eli Lilly) or aspart (Table 1). The mean CGM glucose and people with diabetes are often (Novo Nordisk), the bihormonal iLet for time in range (70–180 mg/dL) were 149 achieved at the expense of increased 7 days with dasiglucagon (4 mg/mL) ±13mg/dLand72±8%,respectively,in hypoglycemia. A novel approach is to and insulin lispro or aspart, or both, us- the insulin-only period, and 139 ± 11 automatically deliver microdose gluca- ing the same glucose target (110 mg/ mg/dL and 79 ± 9%, respectively, in the gon when automation of insulin deliv- dL), in random order. There were no re- bihormonal period. The mean daily car- ery alone is not sufficient to prevent strictions on diet or exercise. The prima- bohydrates consumed to prevent or hypoglycemia. The approach requires a ry outcomes were prespecified iLet treat hypoglycemia were 16 ± 13 g and bihormonal device and a stable form of operational thresholds. The key second- 18 ± 21 g in the insulin-only and bihor- glucagon or glucagon analog. -
Acute Renal Failure in Patients with Type 1 Diabetes Mellitus G
Postgrad Med J: first published as 10.1136/pgmj.70.821.192 on 1 March 1994. Downloaded from Postgrad Med J (1994) 70, 192- 194 C) The Fellowship of Postgraduate Medicine, 1994 Acute renal failure in patients with type 1 diabetes mellitus G. Woodrow, A.M. Brownjohn and J.H. Turney Renal Unit, Leeds General Infirmary, Great George Street, Leeds LSJ 3EX, UK Summary: Acute renal failure (ARF) is a serious condition which still carries a mortality of around 50%. People with diabetes may be at increased risk of developing ARF, either as a complication of diabetic ketoacidosis or hyperosmolar coma, increased incidence of cardiovascular disease, or due to increased susceptibility ofthe kidney to adverse effects in the presence ofunderlying diabetic renal disease. During the period 1956-1992, 1,661 cases of ARF have been treated at Leeds General Infirmary. Of these, we have identified 26 patients also having type 1 diabetes. ARF due to diabetic ketoacidosis is surprisingly uncommon (14 cases out of 23 patients whose notes were reviewed). All cases of ARF complicating ketoacidosis in the last decade have been associated with particularly severe illness requiring intensive care unit support, rather than otherwise 'uncomplicated' ketoacidosis. We discuss the conditions that may result in ARF in patients with diabetes and the particular difficulties that may be encountered in management. Introduction People with diabetes may be at increased risk of Results developing acute renal failure (ARF). Acute pre- copyright. renal failure may occur as a result ofthe severe fluid Of 23 patients with type 1 diabetes complicated by depletion associated with diabetic ketoacidosis and ARF, diabetic ketoacidosis was the main underly- non-ketotic hyperosmolar coma. -
Prediabetes: What Is It and What Can I Do?
Prediabetes: What Is It and What Can I Do? What is prediabetes? Weight loss can delay or prevent diabetes. Prediabetes is a condition that comes before Reaching a healthy weight can help you a lot. diabetes. It means your blood glucose levels are If you’re overweight, any weight loss, even higher than normal but aren’t high enough to be 7 percent of your weight (for example, losing called diabetes. about 15 pounds if you weigh 200), may lower your risk for diabetes. There are no clear symptoms of prediabetes. You can have it and not know it. If I have prediabetes, what does it mean? It means you might get type 2 diabetes soon or down the road. You are also more likely to get heart disease or have a stroke. The good news is that you can take steps to delay or prevent type 2 diabetes. How can I delay or prevent type 2 diabetes? You may be able to delay or prevent type 2 diabetes with: Daily physical activity, such as walking. Weight loss, if needed. Losing even a few pounds will help. Medication, if your doctor prescribes it. If you have prediabetes, these steps may bring your blood glucose to a normal range. But you are still at a higher risk for type 2 diabetes. Regular physical activity can delay or prevent diabetes. Being active is one of the best ways to delay or prevent type 2 diabetes. It can also lower your weight and blood pressure, and improve cholesterol levels. Ask your health care team about activities that are safe for you.